Can IBD Cause Autoimmune Hemolytic Anemia?
Yes, inflammatory bowel disease can cause autoimmune hemolytic anemia (AIHA), though it is a rare extraintestinal manifestation occurring more frequently in ulcerative colitis than Crohn's disease.
Epidemiology and Association
AIHA is an uncommon but well-documented extraintestinal manifestation of IBD. The incidence is estimated at 4.1 per 100,000 patient-years after IBD diagnosis 1. This represents a higher incidence than in the general population, suggesting a non-fortuitous association 1.
Key Clinical Patterns
The association is particularly strong with colonic disease:
- All AIHA patients in one multicenter study had colonic involvement, with 93% having ulcerative colitis 1
- For immune thrombocytopenia (ITP), the distribution was more even between UC and CD 1
- AIHA typically runs in parallel with IBD disease activity 1
Diagnostic Considerations
When evaluating anemia in IBD patients, you must distinguish between multiple causes 2:
Common causes (most frequent):
- Iron deficiency anemia (affects one-third of active IBD patients)
- Anemia of chronic disease
Rare causes to consider:
- Autoimmune hemolytic anemia
- Folate or B12 deficiency
- Bone marrow suppression
To diagnose AIHA specifically:
- Positive direct Coombs test is essential 3
- Most cases are warm AIHA (12 of 14 cases in one series) 1
- Look for absence of visible blood losses 3
- Check for hemolysis markers (elevated LDH, indirect bilirubin, low haptoglobin)
Critical Diagnostic Dilemma: Disease vs. Drug
A major clinical challenge is distinguishing whether AIHA is caused by the underlying IBD or by biologic therapy—this distinction is "complex and almost impossible to establish" 3.
Recent case reports have linked AIHA to:
However, the evidence linking biologics to AIHA remains sparse and not sufficiently compelling according to systematic reviews 7. The temporal relationship and parallel disease activity patterns suggest the underlying IBD is more often the culprit 1.
Clinical Significance and Risk Factors
Patients with AIHA and IBD demonstrate more severe disease characteristics:
- Higher frequency of extraintestinal manifestations (37.5% vs 17% in controls, p<0.001) 1
- Presence of IBD severity hallmarks 1
- Increased morbidity from both conditions
Treatment Approach
First-line therapy:
- Corticosteroids (prednisolone) 3, 6
- Consider discontinuing suspected causative biologic if temporal relationship is clear 5
- Transfusion support as needed 3
Second-line for refractory cases:
- Rituximab is highly effective and has successfully treated AIHA in multiple IBD case reports 3, 5, 6
- Anti-TNF therapy may treat both IBD and AIHA simultaneously 6
Historical options (now less favored):
- Azathioprine or methotrexate with corticosteroids 6
- Splenectomy and/or colectomy (IBD surgery may induce AIHA remission in select cases) 1
Clinical Pitfalls
Do not assume all anemia in IBD is iron deficiency. While iron deficiency is most common, maintain high suspicion for AIHA when:
- Anemia is severe and disproportionate to disease activity
- No visible blood losses are present
- Patient is on biologic therapy (especially vedolizumab or tofacitinib)
- Ferritin is elevated despite anemia (inflammation can mask iron deficiency up to 100 µg/L) 2
Always check a direct Coombs test in unexplained severe anemia in IBD patients, particularly those with colonic involvement or on novel therapies 3, 4.